By using a phi29 3-way junction pRNA nanodelivery system, we have created RNA nanoparticles that are composed of two MED1-targeting siRNAs to silence MED1 and an aptamer that specifically binds to membrane receptor HER2 to allow for targeted delivery into breast cancer cells [Figure 3]. Here, ERBB2 is linked to breast cancer.